Come up with a name for your new list and we'll add to it:
ImmuVen raised a round of funding on August 20, 2010. Investors include
National Institutes of Health.
ImmuVen develops drugs that can be used to treat infectious diseases and cancer. The company features life science technology, T cell receptors, a unique class of immune-targeting therapeutic and diag…